Treatments for renal cell carcinoma are showing effectiveness in the short term, but with the help of new trials, researchers are looking to expand their impact for long term treatment.
Videos
The landscape for patients with renal cell carcinoma could potentially change as the use of immune checkpoint inhibition shows promise for these patients.
A recent study looking at data from three clinical trials involving Nerlynx shows promise for the future of treating patients with HER-2 positive breast cancer who develop CNS metastases.
The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.
Advertisement
Advertisement